|
Post by #NoMoreNeedles on Feb 20, 2019 13:22:06 GMT -5
Wall Street analysts expect MannKind Co. (NASDAQ:MNKD) to announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks Investment Research reports.
|
|
|
Post by mytakeonit on Feb 20, 2019 13:39:04 GMT -5
?? Is the bracketed 17 cents positive or negative? Normally brackets mean negative ... but so many brackets in the post that I'm not so sure ...
|
|
|
Post by #NoMoreNeedles on Feb 20, 2019 13:47:14 GMT -5
Analysts See $-0.17 EPS for MannKind (MNKD)
|
|
|
Post by buyitonsale on Feb 20, 2019 15:34:55 GMT -5
Don’t know what these analysts are looking at but MNKD should book 55M payments from UT plus sales - usual expenses. There are 186M shares. So you do the math but all I know is that Q4 is profitable.
|
|
|
Post by traderdennis on Feb 20, 2019 15:44:43 GMT -5
Don’t know what these analysts are looking at but MNKD should book 55M payments from UT plus sales - usual expenses. There are 186M shares. So you do the math but all I know is that Q4 is profitable. I am not an accountant, Matt is more versed, but how much can be booked in Q4 2018 versus how must be allocated to future quarters based on when the tasks are completed.
|
|
|
Post by buyitonsale on Feb 20, 2019 17:23:00 GMT -5
10M was a research fee 45M was an upfront payment
I see no reason for not booking those in Q4
|
|
|
Post by awesomo on Feb 20, 2019 17:48:46 GMT -5
The UTHR deal is a known entity, however MNKD reports the payments isn't going to matter to Wall Street. So even if they are "profitable" in Q4 from a large upfront sum, it's not going to move the PPS because it isn't sustainable income.
|
|
|
Post by longliner on Feb 20, 2019 19:29:20 GMT -5
The UTHR deal is a known entity, however MNKD reports the payments isn't going to matter to Wall Street. So even if they are "profitable" in Q4 from a large upfront sum, it's not going to move the PPS because it isn't sustainable income. Unless we believe MC, and going forward new molecules will increasingly drive profits. Then it may be sustainable income.
|
|
|
Post by buyitonsale on Feb 20, 2019 19:30:43 GMT -5
I would rather be long MNKD rather than short at this point, no matter what Wall Street thinks. Apparently there has been some interest from institutional holders adding to positions.
|
|
|
Post by sportsrancho on Feb 21, 2019 17:33:24 GMT -5
Don’t know what these analysts are looking at but MNKD should book 55M payments from UT plus sales - usual expenses. There are 186M shares. So you do the math but all I know is that Q4 is profitable. I am not an accountant, Matt is more versed, but how much can be booked in Q4 2018 versus how must be allocated to future quarters based on when the tasks are completed. You probably should go read Spencer article:-)
|
|
|
Post by brianrocco on Feb 22, 2019 9:26:37 GMT -5
Scripts continue to disappoint me, particularly refills relative to December 2017. The lack of growth in refills reported by Symphony MIGHT be explained by past Afrezza users switching to the direct purchase program (which I assume is not included in Symphony figures). I hope Mike C. will discuss this 2/26 if it does in fact help explain the refills.
|
|
|
Post by mnkdfann on Feb 26, 2019 8:15:57 GMT -5
See link for the rest, only posted an excerpt below: ca.finance.yahoo.com/news/mannkind-corporation-fourth-quarter-end-130000699.htmlMannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call GlobeNewswire•February 26, 2019 Conference Call to Begin Today at 9:00 AM ET 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q 2017 on a GAAP basis and 86% when adjusted for a one-time change in estimate recognized in 4Q 2017 4Q 2018 Collaborations and Services Revenue was $10.3 million 2018 Total Revenues were $27.9 million; 137% growth vs. 2017 2018 Afrezza Net Revenue was $17.3 million; 88% growth vs. 2017 2018 Collaborations and Services Revenue was $10.6 million Ended 2018 with $71.7 million in cash, cash equivalents and restricted cash Received $57.2 million in 2018 from license and research agreements with United Therapeutics and Cipla Achieved first-ever quarterly Afrezza gross profit in 4Q 2018 Reduced insulin purchase commitments for 2018 and 2019 by approximately $11.5 million WESTLAKE VILLAGE, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter Results For the fourth quarter of 2018, total revenues were $16.0 million, reflecting Afrezza net revenue of $5.7 million and collaboration and services revenue of $10.3 million. Afrezza net revenue increased 28% on a GAAP basis compared to $4.5 million for the fourth quarter of 2017. In the fourth quarter of 2017, we recognized a $1.4 million change in estimate to Afrezza net revenue; when this adjustment is excluded, Afrezza net revenue increased 86% (non-GAAP) compared to the fourth quarter of 2017, primarily driven by higher product demand and a more favorable mix of cartridges. Collaborations and services revenue increased $10.2 million primarily attributable to the United Therapeutics licensing and research agreements. Afrezza cost of goods sold (COGS) was $5.0 million for the fourth quarter of both 2018 and 2017. Afrezza COGS in the fourth quarter of 2018 reflected a one-time charge of $2.0 million related to an amendment fee associated with our insulin supply agreement, offset by lower inventory write-offs in 2018 of $0.8 million and $0.7 million lower spending associated with manufacturing absorption. Afrezza gross profit was $0.7 million for the fourth quarter, the first quarterly gross profit recognized from Afrezza sales. When the one-time charge of $2.0 million related to the amendment fee is excluded, Afrezza gross profit was $2.7 million (non-GAAP) for the fourth quarter. ... The net loss for the fourth quarter of 2018 was $9.7 million, or $0.06 per share, compared to the $32.8 million net loss in the fourth quarter of 2017, or $0.28 per share. The lower net loss is mainly attributable to an increase in total revenues of $11.5 million and a decrease in total expenses of $9.6 million.
|
|
|
Post by therealisaching on Feb 26, 2019 8:23:17 GMT -5
My quick thoughts:
year end vs year end the balance sheet is in much better shape. Current ratio is now positive. Meaning there are more current assets (cash & accts receivable) vs current liabilities (amounts due in the next 12 months). Paying down the debt over the last 12 months has reduced year to date interest expense by $4MM -- money that can be better used elsewhere such as in the lab or advertising.
Gross profit on Afrezza cogs for the 1st time in the 4th qtr is a milestone.
Progress
|
|
|
Post by peppy on Feb 26, 2019 8:23:43 GMT -5
|
|
|
Post by mnkdfann on Feb 26, 2019 8:23:53 GMT -5
Seeking Alpha summary report: seekingalpha.com/news/3437057-mannkind-misses-0_28-misses-revenueMannKind misses by $0.28, misses on revenue Feb. 26, 2019 8:09 AM ET|About: MannKind Corporation (MNKD)|By: Mamta Mayani, SA News Editor MannKind (NASDAQ:MNKD): Q4 GAAP EPS of -$0.06 misses by $0.28. Revenue of $16.03M (+253.9% Y/Y) misses by $7.48M.
|
|